RESEARCH ARTICLE

The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation

Emilia Antonucci1*, Daniela Poli2*, Alberto Tosetto3*, Vittorio Pengo4*, Armando Tripodi5*, Nicola Magrini6*, Francesco Marongiu7*, Gualtiero Palareti8*, START-Register

1 Department of Experimental and Clinical Medicine, Thrombosis Centre, University of Florence, Florence, Italy, 2 Department of Heart and Vessels, Thrombosis Centre, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, 3 Department of Hematology, Vicenza S. Bortolo Hospital, Vicenza, Italy, 4 Department of Clinical Cardiology, Thrombosis Centre, University of Padua, Padua, Italy, 5 Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 6 Drug Evaluation Unit, WHO Collaborating Centre in Evidence-Based Research Synthesis and Guideline Development, Emilia Romagna Health and Social Care Agency, Bologna, Italy, 7 Department of Medical Sciences, University Hospital of Cagliari, Cagliari, Italy, 8 Coordinator of the START-Register, Bologna, Italy

☯ These authors contributed equally to this work.
* antemilia@virgilio.it

Abstract

START-Register – Survey on anTicoagulated pAtients RegisTer – is an independent, inception-cohort, observational, collaborative database aimed at recording prospectively the clinical history of adult patients starting anticoagulant treatment for any reason and using whatever drug. In this article we present the START-Register and give cross section baseline data focusing on non valvular atrial fibrillation (NVAF). Participants are asked to insert prospectively consecutive patients recorded as electronic file on the web-site of the registry. Required data are: demographic and clinical characteristics of patients, associated risk factors for stroke and bleeding, laboratory routine data, clinical indication for treatment, expected therapeutic range (in cases of treatment with vitamin K antagonists -VKAs). The follow-up is carried out to record: quality of treatment (for patients on VKAs), bleeding complications, thrombotic events, and the onset of any type of associated disease. To date 5252 patients have been enrolled; 97.6% were on VKAs because direct oral anticoagulants (DOAC) have been available in Italy only recently. The median age was 74 years [interquartile range (IQR) 64-80]; males 53.7%. This analysis is focused on the 3209 (61.1%) NVAF patients. Mean CHADS2 score was 2.1±1.1, CHADSVASc score was 3.1±1.3; median age was 76 years (IQR 70-81); 168 patients (5.3%) had severe renal failure [Creatinine clearance (CrCl) <30 ml/min]. Moderate renal failure (CrCl 30-59 ml/min) was found in 1265 patients (39.5%). The analysis of the START-Register data shows that two-third of patients who started chronic anticoagulant treatment had NVAF, one-third of them was > 80 years with high prevalence of renal failure.
Introduction

Oral anticoagulation treatment with vitamin K antagonist (VKA) has been shown to be effective in numerous randomized clinical trials[1], but despite the potential clinical benefits they are underused especially in patients at high risk of bleeding [2]. In the last few years a good deal of effort has been directed towards the development of novel direct oral anticoagulants (DOAC) in order to avoid the difficulties and risks associated with VKA therapy. Several phase III, non-inferiority, large trials in patients with non-valvular atrial fibrillation (NVAF)[3–6], and studies of acute[7–11] or extended [12,13] treatment in patients with venous thromboembolism (VTE) have recently been published investigating the efficacy and safety of 4 different DOAC (dabigatran, rivaroxaban, apixaban and edoxaban) versus standard anticoagulation (in most cases VKAs) for preventing thromboembolic complications in these clinical conditions. In clinical trials however patients are usually carefully selected and there is very close control, factors that may probably result in lower rates of complications and therapeutic failure. This makes it difficult not only to assess the possible value and risk of DOAC in everyday clinical practice, but also to evaluate their health-economic benefits.

Observational studies offer information on clinical routine practice, and could highlight emerging issues. In 2011 we proposed the implementation of a collaborative database to prospectively record the clinical history of patients starting anticoagulant treatment for any reason and whatever the drug used. The study, called START-Register—Survey on anTicoagulated pAtients RegisTer—is designed to provide: a) information on the effects of available anticoagulant treatments, improving the knowledge of epidemiologic, diagnostic, and clinical features of thrombotic diseases; b) to enhance our understanding of the risk-benefits of the various anticoagulant drugs and therapy options. In this article we present the START-Register and its design, and give a cross section of baseline data collected at the moment, in particular focusing on included patients with NVAF.

Material and Methods

START-Register design

The START-Register is an observational, multicenter, dynamic cohort study that includes adults (≥18 years) who start anticoagulation therapy, whatever the drug and dosage used. More recently a branch of the registry also included patients treated with antithrombotic drugs, especially new antiplatelet drugs (START-Antiplatelet); the present article reports only on the anticoagulation branch of the registry. The aim of the START-Register is to collect data on the incidence of adverse events in patients taking anticoagulant, as well of determinants of them and quality of life or patient compliance to treatment. The study design and protocol has been drafted and approved by the Executive Committee that manages the START-Register. The Executive Committee designed a Coordinating Member (G.P.), who first obtained authorization to set up the registry from the Ethical Committee of his Institution (Azienda Ospedaliero-Universitaria, Policlinico S. Orsola-Malpighi, Bologna, Italy) on October 2011 (N = 142/2010/0/0ss”) (NCT02219984). The same institution was entrusted to deploy and maintain the registry central database. The START-Register sets itself an indefinite time limit and is an entirely independent project. Public and private institutions, companies and individuals interested in the issue of anticoagulant treatment (manufacturers of drugs or other goods and services) are asked by the Executive Committee to help funding the registry via unrestricted grants without any right to access database data. Members of the Executive Committee do not receive any payment or fee for their work.

The registry is open to all physicians (called Participants) prescribing anticoagulant therapy and who agree to the Registry protocol. Participants should obtain approval from their local
Institution Review Board. Participants are required to enter patients’ data only after obtaining a written informed consent from the patient. Participants can propose specific studies based on Registry data and have access to pertinent data after acceptance by the Executive Committee. Enrolment of at least 20 patients per year is required to be granted access to study data or propose collaborative studies.

**START-Register procedures**

**Patient eligibility.** Patients ≥18 years who at the time of inclusion have been receiving anticoagulation therapy for no more than 30 days are eligible. The Registry aims at following patients especially during the first 12 months of treatment, though a long-term follow-up is recommended for patients who receive an indefinite anticoagulation. Therefore, patients with life-expectancy <6 months, or not residents in the Participant region, or planning leaving in the next 6 months are not eligible, as well as patients already enrolled in phase II or III clinical studies. Patients enrolled in other observational or phase IV studies can be included in the START-Register.

Follow-up of enrolled patients is mandatory for at least one year. Therefore, participants are required to provide data of all significant events occurring in enrolled patients for at least 12 months, including death, bleeding or thrombotic complications, and development of major organ failure even if use of anticoagulants has been interrupted before 12 months. Participants are required to enrol their patients consecutively, without any a-priori exclusion criteria other than life-expectancy or geographical inaccessibility. Definition of the time-framing for enrolment (e.g., one week every month, or the first month of the year) is left at each participant’s discretion, as long as it provides a random enrolment of patients. Between-participants difference in enrolled patients is anticipated, since some participants may be following patients having preferentially a disease (e.g., atrial fibrillation) or receiving only a particular anticoagulant drug. Participants-stratified analyses will be performed as required to account for these anticipated differences.

**Baseline data.** Patient’s clinical features are recorded by participants on web-based CRF (case report forms). Baseline data are demographic and clinical characteristics of patients, associated risk factors for stroke and bleeding, laboratory routine data, clinical indication for treatment, therapeutic range expected (in cases of treatment with VKA), use of concomitant drugs. Serum creatinine levels are measured by local hospital laboratories, and creatinine clearance (CrCl) is calculated by the Cockroft-Gault formula [14]. Renal failure was defined according to National Kidney Foundation stratification [15].

Patients with non-valvular AF are stratified for stroke risk evaluation according to CHADS$_2$ [16] and CHA$_2$DS$_2$VASc [17] scores while baseline bleeding risk is evaluated by using HAS-BLED score [18]. In patients with venous thromboembolism, the assessment of VTE site and presence of provoking factors is mandatory; presence of biochemical or molecular risk factors is optional.

**Follow-up data.** Participants are required to regularly follow-up enrolled patients at least quarterly, by phone call or ambulatory visit. An ambulatory follow-up visit is mandatory at least annually. Participants are required to provide detailed clinical reports of any relevant clinical outcome occurring in enrolled patients. For patients on VKA, time spent in the therapeutic range (TTR, computed according to the Rosendaal’s method [19]) is recorded every three months for the first year, annually thereafter.

**Events.** Relevant clinical outcomes are major bleeding complications (using the classification recommended by the International Society on Thrombosis and Haemostasis—[20]), any thrombotic event, development of cancer, organ failure, and death. A major bleeding event is
defined as a bleeding event that is accompanied by a decrease in hemoglobin (Hgb) ≥ 2 g/dL, requiring transfusion with ≥ 2 units of packed red blood cells or occurring in a critical site. Clinically relevant non-major bleeding event are classified as bleeding that does not satisfy the criteria for major bleeding but requiring hospital admission or a change in antithrombotic therapy. Minor bleeding events are all bleeding satisfactorily managed in an ambulatory setting. Diagnosis of stroke requires the abrupt onset of focal neurological symptoms lasting at least 24 hours and supported by congruent ischemic lesions at CT or MRI scan. Systemic embolism is defined by symptoms consistent with an acute loss of blood flow to a peripheral artery, which is supported by objective evidence of embolism. Acute MI is defined by thoracic symptoms and troponin elevation ≥ 2 x ULN or significant Q waves. Pulmonary embolism is diagnosed by detection of a new intraluminal filling on spiral CT scan, pulmonary angiogram or ventilation/perfusion lung scan (VPLS). Deep vein thrombosis is diagnosed by thrombus detection in a deep vein by abnormal compression ultrasound (CUS) or venography.

Statistical Analysis

Descriptive analysis was performed. Continuous variables are expressed median and interquartile range (IQR) or as mean ± standard deviation (SD). Categorical variables are expressed as frequencies and percentages. The SPSS software for Windows, version 19 (SPSS Inc, Chicago, IL) was used for data processing.

Results

The inclusion of patients in the registry started in January 2012; at the time of the present analysis (December 2013) 90 Participants, equally distributed in Northern, Central and Southern Italy, had enrolled 5252 patients. As shown in Table 1, males were slightly more represented (53.7%) than females; median age was 74 years and almost one-fourth of all patients were > 80 year old (24.2%). NVAF was the most frequent indication for treatment present in almost two-thirds of all patients (61.1%), followed by VTE (28.6%). VKAs were almost the only type of anticoagulant drug used (Table 1).

Table 1. Patients enrolled in the START-Register, indication for anticoagulation and type of treatment.

| N. | 5252 |
|---|---|
| Males n (%) | 2818 (53.7) |
| Median age, y (interquartile range) | 74 (64–80) |
| Patients aged > 75 years (%) | 2302 (43.9) |
| Patients aged > 80 years | 1268 (24.2) |
| Indication for Anticoagulant treatment n (%) | |
| Non-valvular atrial fibrillation | 3209 (61.1) |
| Venous thromboembolism | 1500 (28.6) |
| Heart prosthetic valves | 223 (4.2) |
| Valvular atrial fibrillation | 104 (2.0) |
| Other | 216 (4.1) |
| Type of treatment (%) | |
| VKA | 5130 (97.6) |
| DOAC | 109 (2.1) |
| LMWH | 13 (0.3) |

VKA = vitamin k antagonist; DOAC = direct oral anticoagulant; LMWH = light molecular weight heparin

doi:10.1371/journal.pone.0124719.t001
The present analysis is focused on the baseline characteristics of the 3209 NVAF patients included in the registry, listed in Table 2. More than half of the patients were > 75 year old, and about one third was 80 years or more. The distribution of patients stratified for stroke risk by using CHADS2 and CHA2DS2-VASc score, and for bleeding risk by using HAS-BLED score is shown in Table 3. Among the small group of 109 patients treated with DOAC, the median age was 76 years [interquartile range (IQR) 70–81]; the mean CHADS2 and CHA2DS2-VASc scores were 2.2 ± 1.3 and 3.1 ± 1.3, respectively; and the mean HAS-BLED score was 2.5± 0.9. The association between VKA and an antiplatelet drug was present in 532 patients (16.6%), while other 50 anticoagulated patients were on double antiplatelet therapy (1.6%) (Table 2). The analysis of renal function showed that 168 patients (5.3%) had severe renal failure (CrCl < 30 ml/min). Moderate renal failure (CrCl 30–59 ml/min) was found in 1265 patients (39.5%), and 329 patients in this group (10.3% of the whole cohort) had CrCl between 30 and 40 ml/min. Table 4 shows some clinical characteristics of NVAF patients enrolled in the study compared to those of patients enrolled in the phase III trials with DOAC and those included in the observational GARFIELD Registry [21].

Table 2. Clinical characteristics of NVAF patients included in the START-Register.

| Characteristics                        | Value          |
|----------------------------------------|---------------|
| N                                      | 3209          |
| Median age, y (interquartile range)    | 76 (70, 81)   |
| Patients > 75 y (%)                    | 1691 (52.7)   |
| Patients 60–69 y                       | 546 (17.0)    |
| Patients 70–79 y                       | 1373 (42.8)   |
| Patients 80–89 y                       | 1002 (31.2)   |
| Patients ≥ 90 y                        | 55 (1.7)      |
| Males (%)                              | 1770 (55.2)   |
| Chronic NVAF (%)                       | 1691 (52.7)   |
| Type of treatment                      |               |
| Warfarin                               | 3070 (95.7)   |
| Acenocoumarol                          | 38 (1.2)      |
| Dabigatran- Rivaroxaban                | 101 (3.1)     |
| Past medical history (%)               |               |
| Heart failure                          | 463 (15.0)    |
| Hypertension                           | 2673 (84.9)   |
| Diabetes                               | 639 (20.6)    |
| Coronary Artery Disease                | 616 (19.9)    |
| Peripheral Artery disease              | 169 (5.5)     |
| Previous stroke/TIA                    | 448 (14.6)    |
| Previous major bleeding                | 64 (2.0)      |
| Other characteristics at inclusion (%) |               |
| CHADS2 score (mean±SD)                 | 2.1±1.1       |
| CHA2DS2-VASc score (mean±SD)           | 3.0 ± 1.3     |
| HAS-BLED score (mean±SD)               | 2.5± 1.0      |
| Active cancer                          | 76 (2.5)      |
| Creatinine clearance <30 ml/min        | 168 (5.3)     |
| Antiplatelet drugs + VKAs              | 532 (16.6)    |
| Dual antiplatelet drugs + VKAs         | 50 (1.6)      |

VKA = vitamin k antagonist; TIA = Transient ischemic attack

doi:10.1371/journal.pone.0124719.t002
Finally, we estimated the number of NVAF patients who would have been compliant with the rules recently issued by the Italian Regulatory Drug Agency (AIFA) to receive from the National Health System complete reimbursement of treatment with one of the marketed DOAC.

For VKA-naïve patients (as were the patients included in the registry), there were two criteria established by the Agency: a) the concurrent presence of two clinical characteristics: a CHA2DS2-VASc score above a specific value that was different for the various drugs (see Table 5) and a HAS-BLED score > 3 (for all the drugs); or b) the impossibility of performing the VKA-therapy due to the presence of objective difficulties to comply with the need for the periodic laboratory controls (a condition that was not relevant in our series of patients). After exclusion of patients with severe renal insufficiency (following the criterion established by drug producers) the number of patients who would have been compliant with the two a) criteria was calculated. In line with the criterion of a HAS-BLED score > 3, which was the most restrictive, only about 15% of patients qualified for being treated with DOAC.

Table 3. Clinical characteristics of AF patients in relation to stroke and bleeding risk stratification models.

| Score | CHADS2 n(%) | CHA2DS2-VASc n(%) | HAS-BLED* n (%) |
|-------|-------------|--------------------|-----------------|
| 0     | 196 (6.6)   | 59 (2.0)           | 77 (2.5)        |
| 1     | 842 (28.2)  | 267 (9.0)          | 362 (11.9)      |
| 2     | 1108 (37.1) | 729 (24.6)         | 1024 (33.6)     |
| 3     | 496 (16.6)  | 981 (33.1)         | 1132 (37.1)     |
| 4     | 274 (9.2)   | 532 (17.9)         | 409 (13.4)      |
| 5     | 63 (2.1)    | 301 (10.1)         | 45 (1.5)        |
| 6     | 5 (0.2)     | 84 (2.8)           | 1 (0.0)         |
| 7     | 14 (0.5)    |                    |                 |
| 8     |             |                    |                 |
| 9     |             |                    |                 |

* all patient were naïve, no time in therapeutic range

doi:10.1371/journal.pone.0124719.t003

Table 4. Some characteristics of NVAF patients enrolled in START-Register, compared to those in the GARFIELD Registry and in randomized trials on DOAC.

|                  | START       | Garfield [19] | RE-LY [3]   | Rocket-AF [4] | Aristotle [5] | Engage AF [6] |
|------------------|-------------|---------------|-------------|---------------|---------------|---------------|
| Age yrs          | 74.6±9.6    | 70±11         | 72±9        | 73 (65,78)    | 70 (63,76)    | 72 (64,78)    |
| CrCl ml/min %    |             |               |             |               |               |               |
| 30–59            | 39.7        | 11.4          |             |               |               |               |
| 30–50            | 23.9        | 19.3          | 20.8        | 15.1          | 19.3          |               |
| < 30             | 5.3         | 2.0           | Excluded    | Excluded      | 1.5*          | Excluded      |
| < 15             | 0.02        |               |             |               |               |               |
| BMI              | 28.3±5.1    | 28±5          | 82.6 Kg ±19.9 | 28 (25,32)    | 82 Kg (70–95) | NA            |
| History of ACS % | 20          | 10            | 17          | 17            | 15            | NA            |
| Diabetes %       | 21          | 22            | 23          | 40            | 19.4          | 36.1          |
| CHADS2 score     | 2.1±1.1     | 1.9±1.2       | 2.1±1.1     | 3.5±0.9       | 2.1±1.1       | 2.8±1.0       |

DOAC = direct oral anticoagulant
CrCl = creatinine clearance
Data are expressed as mean ± SD, or median (IQR), or %; NA = not available
* = patients with CrCl<25 ml/min were excluded

doi:10.1371/journal.pone.0124719.t004
Discussion

This is the first paper presenting the Start-Register, an ongoing, collaborative, prospective, observational Register aimed at recording the clinical history of patients starting anticoagulant treatment, whatever the drug and dosage used and whatever the indication to treatment. Data reported in this paper describe the baseline characteristics of patients included after the first two years of activity of the Register, in particular focusing on those with NVAF who in the large majority received warfarin. In fact, only a small group of included patients were treated with DOAC. The DOAC currently available and reimbursable by the National Health System for treatment of NVAF (dabigatran, rivaroxaban, apixaban) have been marketed in Italy only during the last few months; furthermore the Italian Regulatory Drug Agency (AIFA) has established strict regulations to allow the prescription of a DOAC limiting in this way their use. Since the Participants in the Registry are equally distributed across Italy, the present inception-cohort can be considered representative of patients starting anticoagulation throughout Italy. Patients were relatively old, with just under half of them being > 75 years old at inclusion. Non valvular atrial fibrillation was the most frequent indication for anticoagulation (61.1%), followed by VTE (28.6%).

The analysis of NVAF subjects shows that the mean age of patients enrolled was slightly higher than that observed in the trials on DOAC and in the GARFIELD Registry [21]. One third of our patients were > 80 years old at inclusion; this confirms the advanced age of patients treated for this indication, this subpopulation is not sufficiently represented in phase III trials on DOAC (7–9,11). Other clinical characteristics of our cohort are comparable to those observed in patients enrolled in observational registries [21–23] Instead, our NVAF cohort shows a particularly high prevalence of moderate renal failure (CrCl 30–59 ml/min). As a matter of fact, moderate renal failure is present in about 40% of patients enrolled in the Registry compared with only 11% in GARFIELD’s cohort and 15–20% in trials with DOAC. In addition, the percentage of patients with severe renal failure, a group of patients excluded from the above trials, is higher than in the GARFIELD Registry, reaching 5% of our NVAF population. The presence of renal failure appears to be particularly important in the START Registry NVAF population. This finding can be in part explained by the older age of our population, that is represented for 45% by patients with ≥75 years. The cohort of patients with moderate renal failure is of particular clinical interest because patients are exposed to a rapid worsening of the renal function in case of intercurrent diseases, such as infections or heart failure. If treated with a DOAC this group of patients should be carefully monitored. DOAC are in fact mainly cleared via the kidneys—though with important differences between the available drugs—and tend to accumulate in case of kidney failure, with a subsequent

---

**Table 5. Number of anticoagulation-naive patients with NVAF who at the moment of inclusion in the START-Register would have been compliant with the lower limit of creatinine clearance declared by the drug companies and with the criteria established from the Italian Regulatory Agency (AIFA), in order to be potentially treated with DOA.** The criterion regarding the individual difficulties in performing the laboratory control of INR, as well as the percentage of time in range (all the START-Register patients were VKA-naive at inclusion) have not been taken into account for this evaluation.

| Drug    | Number of patients eligible | CHA²DS²-VASc | HAS-BLED |
|---------|----------------------------|--------------|----------|
| Dabigatran* | 3041                       | ≥ 1 = 2746/3041 (90.3) | > 3 = 932/3195 (29.2) |
| Rivaroxaban** | 3195                       | > 3 = 455/3195 (15.0)  | > 3 = 455/3195 (14.2%) |
| Apixaban¶  | 3195                       | > 3 = 455/3195 (14.2%) | > 3 = 455/3195 (14.2%) |

CrCl = creatinine clearance
* after exclusion of 168 patients with CrCl < 30 ml/min
** after exclusion of 14 patients with CrCl < 15 ml/min
¶ after exclusion of 14 patients with CrCl < 15 ml/min

DOI: 10.1371/journal.pone.0124719.t005
increase in bleeding risk. In our cohort moderate renal failure is found in about 40% of patients, and about 10% have CrCl < 40 ml/min. It is worth noting that about 10% of patients treated with DOAC in our cohort are in this high risk group.

We are aware that our study has limitation. The participants to the Registry are mainly Anticoagulation Clinics and cardiologists, instead neurologists and general practitioners are less represented. However, consecutive patients enrolment is mandatory so limiting the selection of patients. In addition, participants in the Registry are geographically widely distributed across Italy, involving Centres of some small and main Italian cities.

Finally, it should be noted that, in accordance with the regulations established by the Italian Regulatory Drug Agency (AIFA), only a small portion (approximately 15%) of NVAF patients included in the Registry could have received the treatment with one of the available DOAC and reimbursed by the Italian National Health System. In fact, only a small portion of VKA-naïve NVAF patients proved to be compliant with the AIFA’s criteria for treatment reimbursement in. These criteria have been defined on the basis of the characteristics of patients enrolled in DOACs phase 3 trials, and not on the basis of cost-effectiveness analysis. However, this choice is questionable for several aspects. One of these is the indication to use DOAC in patients with a HAS-BLED score ≥ 3. These drugs have shown a safety performance at least similar to that of VKA, and in some cases even better, without any specific relationship with the HAS-BLED. Furthermore, two items that concur in the scoring, or are not available in VKA-naïve subjects (labile-INR, 1 point), or are conditions that may put at risk the use of DOAC (renal or liver function impairment, 1 point each). As regards the CHA2DS2VASc score evaluation, it is singular that the minimal level accepted for reimbursement differs so widely across the three available drugs. Unless the Agency is aware of results not available in the published trials, it is difficult to understand why patients should have a score of 4 or more to receive reimbursement with rivaroxaban, of 3 or more with apixaban, while a score of 1 is sufficient to be treated with dabigatran. For the above reasons, and for the need of fair and objective comparison of performances of different DOAC in a context of real life, we hope that these regulations can soon be changed by our Agency.

In conclusion, the analysis of baseline characteristics of the inception-cohort anticoagulated patients included in the START Register shows that almost two-third of patients started chronic anticoagulant treatment because of NVAF, and one-third of them is > 80 years at inclusion. The prevalence of renal failure is especially high in our NVAF population, since about 40% of patients have moderate and > 5% severe renal failure, the latter being an exclusion criterion in almost all the trials on DOAC. The START Register is now prospectively including non-selected new anticoagulated patients and collecting all the clinical data regarding their initial conditions and follow-up. The clinical use of DOAC started very recently in our country and the Registry will allow the clinical history of patients treated with conventional or newly proposed anticoagulant agents to be compared.

Acknowledgments

The following Investigators and Centres participated:

Sophie Testa, Oriana Paoletti, UO Laboratorio Analisi, Centro Emostasi e Trombosi A O Istituti Ospitalieri di Cremona, Cremona
Vittorio Pengo, Dipartimento di Scienze Cardio-Toraco-Vascolari, Centro Trombosi, AOU Padova,
Anna Falanga, Teresa Lerede, USC SIMT, Centro Emostasi e Trombosi, Ospedale Papa Giovanni XXIII, Bergamo
Giuliana Guazzaloca, UO di Angiologia e Malattie Coagulazione "Marino Golinelli", AOU S. Orsola-Malpighi, Bologna, Bologna
Daniela Poli, Rossella Marcucci, Dipartimento del Cuore e dei Vasi, SOD Malattie Aterotrombotiche, AOU-Careggi, Firenze
Antonietta Piana, Francesco Cibecchini, Centro Prevenzione e CurA Malattie Tromboembo-
liche e Centro TAO, I.R.C.C.S. Azienda Ospedaliera Universitaria San Martino-IST, Genova
Lucia Ruocco, UO Laboratorio Analisi Cliniche Cisanello, Ambulatorio Antitrombosi, AOU Pisana, Pisa
Giacomo Lucarelli, Centro Trombosi, Ospedale Regionale F. Miiuli, Acquaviva delle Fonti (Bari)
Carmelo Paparo, Centro Trombosi, Patologia Clinica Ospedale Maggiore, Chieri (Torino)
Giuliana Martini, Giovanni Scovoli, U.O Laboratorio Analisi Centro Emostasi, Spedali
Civili di Brescia, Brescia
Salvatore Bradamante, Centro Trasfusionale, Centro Emostasi e Trombosi, Ospedale SS Annunziata, Taranto
Giuseppe Malcangi, Centro Emofilia e Trombosi, Policlinico di Bari, Bari
Maria Lombardi, Centro Emostasi e Trombosi, UO Medicina Interna e Angiologia, AU
Parma, Parma
Antonio Insana, SC Patologia Clinica, Ospedale Santa Croce Moncalieri, Moncalieri (Torino)
Andrea Toma, Pietro Barbera, UOC di Patologia Clinica, Ambulatorio Terapia Anticoagula-
lante Orale, O.C. "L.Cazzavillan" Arzignano, (Vicenza)
Lucilla Masciocco, Pasquale Saracino, Angelo Benvenuto, UOC Medicina Interna, Centro
Controllo Coagulazione, Centro FCSA 487, Presidio Ospedaliero Lastaria, Lucera (Foggia)
Claudio Vasselli, Laboratorio Patologia Clinica, Policlinico Casilino- Roma, Roma
Rosella Sangiorgio, Centro "Emostasi e Trombosi", Presidio Ospedaliero Di Lecco, Azienda
Ospedaliera della Provincia di Lecco, Lecco
Luciano Crippa, Ambulatorio Emostasi e Trombosi, UO Patologie Trombotiche Ospedale
San Raffaele, Milano
Simona Pedrini, Federica Bertola, Servizio di Laboratorio, Istituto Ospedaliero Fondazione
Poliambulanza Brescia
Serena Rupoli, Clinica di Ematologia, AOU- Ospedali Riuniti di Ancona, Ancona
Domenico Lione, UOC di Patologia Clinica, Ospedale A Perrino, Brindisi
Samantha Pasca, SOS Malattie Emorragiche e Trombotiche Dipartimento Medicina Trasfu-
sionale AOU "Santa Maria della Misericordia", Udine
Vanessa Roldan, Hospital Universitario Morales Meseguer, Murcia, Espagna
Vincenza Rossi, Centro Emostasi e Trombosi, AO Cosenza, Cosenza
Eugenio Bucherini, SS Medicina Vascolare- Angiologia, Ambulatorio Anticoagulanti, Ospede-
dale Civile di Faenza, Faenza (Ravenna)
Paolo Gresele, Medicina Interna e Vascolare, AOU-Perugia, Perugia
Catello Mangione, Ospedale S.Caterina Novella, Sezione Trasfusionale, Galatina, (Lecce)
Silvana Cicconi, Laboratorio Analisi, San Severino Marche (Macerata)
Paola Casasco, Centro diagnosi trombosi e sorveglianza terapia anticoagulante, Servizio
medicina trasfusionale, Asl AL, Tortona (Alessandria)
Giancarlo Castaman, Alberto Tosseto, Divisione di Ematologia, Centro Malattie Emorra-
giche e Trombotiche, Ospedale San Bortolo, Vicenza
Nicola Lucio Liberato, UO Medicina Interna, Ambulatorio Terapia Anticoagulante Orale, AO Provincia di Pavia, Pavia
Cesarina Bendotti, AO Bolognini-Seriate, Dip Medicina Generale, Ospedale di Piario, Piario (Bergamo)
Vincenzo Oriana, Centro Emofilia—Presidio Ospedaliero Morelli, Reggio Calabria
Paolo Manotti, Medicina di Gruppo San Marco, Boretto, (Reggio Emilia)
Maddalena Loredana Zighetti, SIMT- AO San Paolo, Milano
Paolo Pedico, UO di Medicina Trasfusionale, Presidio Ospedaliero Dimiccoli, Barletta (Bari)

Enzo Fidone, SIMT di modica- Ospedale Maggiore di Modica, Modica, (Ragusa)
Carla Lombardo, U.O. Patologia Clinica, Ospedale Ajello, Mazara Del Vallo (Trapani)
Ornella Onorina Paci, P. O. Mazzoni, Servizio di Immunologia, Allergologia e Trasfusionale, Ascoli Piceno

Simona Pezzella, UO Medicina Trasfusionale, Centro TAO, PO Battaglia, Battaglia, (Salerno)
Mario Pezzo, Ospedale di Suzzara SpA, Suzzara (Mantova)
Antonio Ciampa, Dipartimento Medicina di Laboratorio, Laboratorio Analisi, Ospedale San Giuseppe Moscati, Avellino
Italiano Maccaroni, U.O. Patologia Clinica, Ospedale di Recanati, Recanati, (Macerata)
Gabriella Molini, Ambulatorio Monitoraggio Terapia anticoagulante. Ospedale di Assisi, (Assisi)

Aurora Ciardiello, Centro Trasfusionale, Ospedale Maria Vittoria, Torino
Marco Marietta, Malattie Coagulazione Azienda Ospedaliero-Universitaria di Modena, Modena

Anna Turrini, Laboratorio Analisi, Ospedale Sacro Cuore, Negrar (Verona)
Doris Barcellona, UOC Medicina Interna, Centro Emocoagulopatie, AOU Cagliari, Cagliari

START-Register Stering Committee:
Prof. Gualtiero Palareti, Chair (Bologna); Dott. Nicola Magrini, (Bologna) Prof. Francesco Marongiu, (Cagliari) Prof. Vittorio Pengo (Padova), Dott.ssa Daniela Poli, (Firenze); Prof. Armando Tripodi, (Milano).

Author Contributions
Conceived and designed the experiments: GP NM FM VP DP AT. Analyzed the data: EA DP. Wrote the paper: EA DP AT GP.

References

1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e44S–88S. doi:10.1378/chest.11-2292 PMID: 22315269
2. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008; 29: 1181–1189. doi:10.1093/eurheartj/ehn139 PMID: 18397874
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139–1151. doi:10.1056/NEJMoa0905561 PMID: 19717844
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883–891. doi: 10.1056/NEJMoa1109636 PMID: 21830957
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981–992. doi: 10.1056/NEJMoa1107099 PMID: 21870978
6. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 369: 2093–2104. doi: 10.1056/NEJMoa1310907 PMID: 24251359
7. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342–2352. doi:10.1056/NEJMoa0906598 PMID: 19966341

8. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Lensing AW, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499–2510. doi:10.1056/NEJMoa1007903 PMID: 21218814

9. Buller HR, Prins MH, Lensing AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287–1297. doi:10.1056/NEJMoa1113572 PMID: 22449293

10. Buller HR, Decousus H, Grosso MA, Middeldorp S, Prins MH, Raskob GE, et al. Edoxaban versus warfarin for symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–1415. doi:10.1056/NEJMoa1306638 PMID: 23991658

11. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808. doi:10.1056/NEJMoa1302507 PMID: 23808982

12. Schulman S, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709–718. doi:10.1056/NEJMoa1113697 PMID: 23425163

13. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699–708. doi:10.1056/NEJMoa1207541 PMID: 23216615

14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41. PMID: 1244564

15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–266 PMID: 11904577

16. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation—Stroke risk stratification in patients taking aspirin. Circulation. 2004; 110: 2287–2292. doi: 10.1378/chest.09-1584 PMID: 15477396

17. Lip GY, Nieuwlaat R, Pisters R, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137: 263–272. doi: 10.1378/chest.09-1584 PMID: 19762550

18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093–1100. doi: 10.1378/chest.10-0134 PMID: 20299623

19. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69: 236–239. PMID: 8470047

20. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3: 692–694. PMID: 15842354

21. Kakkar AK, Muller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013; 8: e63479. doi:10.1371/journal.pone.0063479 PMID: 23704912

22. Volterrani M, Iellemo F, Rosano G, Guarini P, Pusineri E, Bonassi S, et al; SICOA (Società Italiana Cardiologia Ospedalità Accreddata) Investigators. Anticoagulation in “real world” patients with atrial fibrillation in Italy: results from the ISPAG (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. Int J Cardiol. 2013; 168:4729–4733 doi:10.1016/j.ijcard.2013.07.169 PMID: 23948115

23. Kirchhof P, Ammentorp B, Darius H, De Caterina R, De Heuzey JY, Schilling RJ, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014; 16:6–14. doi: 10.1093/europace/eut263 PMID: 24084680